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ABstRAct
Resistant starch is a complex carbohydrate that reaches the colon where it can be 
fermented by the colonic microflora resulting in production of short chain fatty acids 
(SCFA), in particular butyrate. RS effects on colorectal tumorigenesis are contrasting 
and protection remains controversial. Butyrate has an important role as the preferred 
metabolic fuel and regulator of colonocyte proliferation, differentiation and apoptosis 
and may play a role in cancer prevention. Thus variation in butyrate production from 
different substrates might explain the variation in effect of RS. This study evaluated the 
hypothesis that feeding dietary resistant starch (as high amylose maize starch) would 
protect against azoxymethane (AOM)‑colon carcinogenesis and favorably influence 
the colonic luminal environment. Male Sprague‑Dawley rats (n = 90) were provided 
one of three diets: Control (without added dietary fibre or RS), 10% HAS (contained 
100 g/kg raw high amylose maize starch) or 20% HAS (contained 200 g/kg high 
amylose maize starch). Rats were fed their experimental diets for four weeks after which 
they were injected with AOM (15 mg/kg) during the fifth and six week. Colons were 
resected (25 weeks post second injection) for evaluation of tumor formation, apoptosis, 
proliferating cell nuclear antigen (PCNA) labelling index and short chain fatty acid levels. 
Feeding resistant starch significantly reduced the incidence (p < 0.01) and multiplicity 
(p < 0.05) of adenocarcinomas in the colon compared to the Control diet. Both doses of 
HAS resulted in similar protection against colon tumorigenesis. Feeding RS significantly 
increased total SCFA concentrations, including butyrate in the distal colon. Apoptosis 
(p < 0.01) was also enhanced while PCNA labelling index was reduced (p < 0.01) in 
the distal colon with resistant starch feeding. The protective effect of consumption of RS as 
dietary high‑amylose cornstarch against colon cancer development appears to be related 
to active fermentation in the colon, particularly through production of butyrate.
IntRoductIon
Diet has long been recognised as an important environmental factor in the aetiology 
of colorectal cancer (CRC).1 Evidence from numerous studies suggests a protective role 
of dietary fibre on colorectal cancer.2,3 While less research has been conducted on a role 
for dietary starch on colorectal cancer risk, there is evidence that starch may protect.4 
In an international correlative study (across 12 populations) Cassidy et al.5 found a strong 
inverse associations between starch intake and both colon and rectal cancer. The effect 
remained statistically significant when adjusting for fat and protein intake. The authors 
assumed in this study that around 5% of all starch consumed were resistant to digestion 
and this component termed ‘resistant starch’ may have contributed to the protective effect 
on CRC.
Resistant starch is defined as a component of dietary starch that is not absorbed in the 
small intestine of healthy individuals and thus reaches the colon undigested, similar to 
dietary fibre where it also is subjected to fermentation by the colonic anaerobic bacteria.6 
Resistant starch can be classified into four main types based upon structural considerations 
and bacterial degradation.6 RS1 includes physically entrapped starch within whole plant 
cells and food matrices (e.g., coarsely milled grain). RS2 consists of native starch granules 
that are highly resistant to digestion by a-amylases (e.g., green banana, high amylose maize 
starch). RS3 comprises retrograded starches, formed when starchy foods are cooked and 
cooled. RS4 comprises chemically modified starches (e.g., esterified starches) where the 
modification interferes with the amylolytic activity of digestive enzymes. Each RS type has 
different characteristics and different fermentation patterns7 which may lead to different 
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effects on luminal environment. As a consequence, different types of 
resistant starch should not be considered equivalent and may have 
different effects on CRC development.
A number of studies have examined the effect of resistant 
starch on experimentally induced colorectal carcinogenesis. These 
are summarised in Young et al.4 and the results are conflicting. 
More recently hydrothermally treated RS3 protected against 
dimethylhydrazine (DMH)-induced colon carcinogenesis8 and high 
amylose maize starch protected against AOM-induced colon cancer.9 
There are several explanations for the varying results between the 
reported studies: the different carcinogen protocols (dose and 
duration), differences in starch type, feeding regimens, lack of 
effect on fermentation parameters and the comparative control diet. 
Some of these will alter luminal conditions known to have a major 
influence on colonic oncogenesis.10,11
RS may protect through mechanisms associated with its fermen-
tation in the colon. RS like that of dietary fibre is fermented by the 
colonic microflora resulting in the production of short chain fatty 
acids (SCFA) and gases (CO2, CH4, H2).
11 The SCFA butyrate has 
generated the most interest as it may be protective against colorectal 
cancer.12,13 Although butyrate is the primary energy source for 
colonic epithelium,14 it inhibits growth of cancer cells in vitro and 
forces a more normal differentiated phenotype.12 In addition, it is a 
potent pro-apoptotic agent15 which might aid removal of cells with 
damaged DNA. Colonic production of butyrate by fermentation is 
associated with reduced rate of aberrant crypt foci16 and tumor mass 
in an animal model, provided that fermentation is active in the distal 
colon.17
Resistant starch may also protect through broader mechanisms 
associated with fibre such as alterations of gut microbiota to a more 
beneficial state,18 reducing bile acid metabolism,19 increasing faecal 
bulk, decreasing transit time and reducing pH levels in colonic 
lumen.11 All these effects might contribute to protection and 
colorectal cancer.
This study investigated the effects of feeding increasing 
concentrations of the RS2 high amylose cornstarch (HAS) to rats on 
chemically-induced colorectal cancer. We explored the relationship 
between effect of RS on SCFA production and cellular processes of 
relevance to carcinogenesis, specifically epithelial proliferation and 
apoptosis. The purpose was to determine if protection occurred as a 
result of active fermentative production of butyrate.
mAtERIALs And mEtHods
Animals and diets. A total of 90 male Sprague-Dawley rats, five 
weeks of age, were obtained from the Animal Resource Centre, 
Perth, Western Australia. Animals were divided randomly into three 
experimental groups and housed three per plastic cage in an animal 
holding room under controlled conditions of 22 ± 2°C (SD), 80 ± 
10% humidity, and 12 h light/dark cycle. Animals were given free 
access to water and weighed weekly throughout the study.
The diets were modified forms of the AIN-76a standard for 
purified diets for rats and mice.20 Each group of animals was fed 
an experimental diet based on the control diet (Table 1). Choline, 
methionine, minerals, and vitamins were added as previously.21 The 
first group “control” consumed a diet containing no added fibre or 
resistant starch. The second group “10% HAS” were fed a diet that 
contained 100 g/kg raw high amylose maize starch (HAS). The third 
group “20% HAS” were fed a diet that contained 200 g/kg HAS. 
High amylose maize starch (Hi-maize® 958) a RS2 was used as the 
source of resistant starch and was supplied by National Starch and 
Chemical Company, Bridgewater, New Jersey, USA. High amylose 
maize starch was added to the diets at the expense of an equal amount 
of digestible cornstarch.
Experimental procedure. After four weeks on experimental diets 
each rat received s.c. injections of azoxymethane (15 mg/kg body 
weight) Sigma Chemical Co., St Louis, MO) once weekly for two 
weeks and then maintained on their dietary regimen until sacrifice 
(25 weeks post second AOM injection). The rats in each group were 
weighed once weekly. In the fourth week of the experiment fifteen 
rats from each treatment group were placed in metabolic cages to 
measure faecal output, food intake and collect urine. Fresh faecal 
samples were collected from each rat and diluted in 3 volumes of 
internal standard solution (heptanoic acid, 1.68 mmol/L) and stored 
at -20°C for later analysis of SCFA concentrations on the last three 
days of the experimental period by gently handling the rats until they 
produced a faecal sample.
As scheduled, all rats were killed by CO2 asphyxiation. After 
laparotomy, the entire stomach, small intestine and large intestine 
were resected. They were opened longitudinally and the caecal 
and colonic contents collected for SCFA measurements. Distal 
and proximal colonic content and caecal digesta were collected 
and diluted in 3 volumes of internal standard solution (heptanoic 
acid, 1.68 mmol/L) and stored at -20°C for later analysis of SCFA 
concentrations. The distal portion was collected from lower 1/3 of 
colon while the proximal portion was taken from “herring bone” 
area. The small intestine and colon were examined for intestinal 
tumors, and the location and number of tumors were assessed with a 
dissection microscope (magnification 20x) and recorded.
The Flinders University of South Australia Animals Welfare 
Committee approved all experimental procedures.
Colonic tumors. Using a light microscope (magnification 40x), the 
colon were scored for tumor number and location by an independent 
observer who was unaware of dietary treatment as (described 
previously in ref. 22). Tumors were removed and embedded in 
paraffin (5 mm) for histopathological analysis. All tumors were 
examined histologically and evaluated by an independent observer 
based on the criteria of Pozharisski.23 Adenoma was characterized 
Table 1	 Composition	of	experimental	diets		
	 (g/100g	diet).1,2
Ingredient control 10% HAs 20% HAs
Casein 20.00 20.00 5.00
Corn starch 46.15 36.15 26.15
High amylose maize starch ‑ 10.00 20.00
Corn oil 18.00 18.00 18.00
Sucrose 10.95 10.95 10.95
dl‑Methionine 0.3 0.3 0.3
Choline 0.1 0.1 0.1
Mineral mix2 3.5 3.5 3.5
Vitamin mix2 1.0 1.0 1.0
1High amylose maize starch used as source of resistant starch. 2AIN-76 vitamin and mineral 
mixtures.20
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by expansion of the mucosa layer, reduction in goblet cell number, 
cellular dysplasia, moderate loss of mucosal architecture by glandular 
growth and lack of invasion through the basement membrane. 
Adenocarcinoma was identified from the following characteristics: 
typical cytological change, prominent cellular atypia, loss of cell 
polarity, marked distortion of glandular architecture and invasion.23
Epithelial cellular processes. Colon sections (0.5 cm x 0.5 cm) 
in 70% ethanol were cut from distal segments of the colon free of 
neoplasms and embedded in paraffin. Paraffin-embedded sections 
(5 mm) were stained with hematoxylin and evaluated under a light 
microscope for apoptotic cells. Apoptotic cells were identified in 
20 randomly chosen intact crypts by cell shrinkage, presence of 
condensed chromatin and sharply delineated cell borders surrounded 
with a clear halo as reported previously.24
To assess the proliferative activity and the distribution of 
proliferating cells in the colonic crypts the proliferating cell nuclear 
antigen (PCNA) was performed using standard immunohistochemical 
procedures. Briefly, deparaffinized sections were rehydrated in a 
graded series of ethanol from 100% to 50% and then to distilled 
water. The primary mouse monoclonal antibody (PC-10, Santa 
Cruz, USA) was placed on the slides (1/500 dilution) and incubated 
overnight at room temperature. A Level 2 Ultra Streptavidin 
detection system (Signet Laboratories, Inc, USA) was used utilising 
biotinylated goat anti-mouse as the secondary antibody. The slides 
were counterstained for 3 min with haematoxylin. In all cases, an 
independent observer who was unaware of the experimental dietary 
treatment determined the quantification of proliferative cells. The 
labelling index (LI), which is calculated as the number of positive 
cells in divided by the total number of cells in each crypt column 
multiplied by 100.
SCFA analysis. SCFA including acetate, propionate and butyrate 
were determined in the caecal, colon contents and faeces of rats as 
(described previously in ref. 21).
Statistical analysis. The effect of RS on tumor incidence and 
number were analysed used log binomial generalized linear models. 
Poisson regression models were used to analyse differences between 
treatments for tumor numbers in the colon. For analysis of SCFA 
concentrations, apoptosis and cell proliferation a One-way analysis 
of variance with Ryan-Einot-Gabriel-Welsch multiple stepdown 
post-hoc procedure was undertaken. Data are presented as the mean 
(SEM) for each treatment group. Means with the same letter are 
not statistically significantly different at p ≤ 0.05. The relationship 
between caecal, colonic and faecal parameters with apoptosis, cell 
proliferation and colon tumor incidence was determined using 
the Bivariate Correlation procedure utilising Pearson’s correlation 
coefficient. A value of p < 0.05 was used as the criterion of 
significance. The statistical package Stata 8 was used for all analyses.
REsuLts
Body weights, food intake and water intake. There were no 
significant differences in the body weight gain (g/30 wk), water or 
food intake between the groups (Table 2).
Caecal and faecal parameters. The wet weight of caecal contents 
increased as the HAS content of the diet increased (Table 2). This was 
accompanied by an increase in caecal tissue weights and a reduction 
in the pH of caecal contents. Faecal pH showed a similar pattern of 
change to that in the caecum. Faecal output in the rats increased as 
the HAS content of the diet increased (Table 2).
Colonic neoplasms. The effects of diet on incidence (proportion 
of rats who develop neoplasia), type of neoplasm (adenoma or cancer) 
in the colon and number of neoplasms per colon are shown in Table 
3. There was a significant decrease in the incidence of all colonic 
neoplasms with the 20% HAS compared to the Control group. 
There was a 50% decrease in colon cancer incidence when HAS 
was incorporated into to the diet irrespective of dose compared to 
Control group (p < 0.01). Both doses of HAS significantly decreased 
the number of cancers per rat colon (tumor burden) compared to the 
Control group (p < 0.05).
Effects of diet on apoptosis and cell proliferation in colon. The 
frequency of apoptotic cells which were detected by haematoxylin 
staining are shown in Figure 1. There was a significant increase in 
the number of apoptotic cells in the distal colonic crypts of the HAS 
groups compared with the Control group (p < 0.01).
Cell proliferation was evaluated by assessing the PCNA staining 
in the distal colonic crypts, and Figure 2 shows the PCNA labelling 
index for the different groups. Both doses of HAS significantly 
lowered the PCNA labelling index compared to the Control group 
(p < 0.01).
Table 2	 Effect	of	resistant	starch	and	indigestible		
	 protein	on	weight	gain,	feed	intake	and	faecal		
	 output	in	rats1,2
  treatment Group
 control 10% HAs 20% HAs
Weight gain (g/30 wk) 570.5 (9.2) 530.0 (16.9) 539 (12.3)
Daily water intake (ml) 24.3 (0.8) 28.7 (2.2) 27.5 (2.2)
Daily food intake (g/d) 18.0 (0.4) 18.2 (0.8) 17.7 (0.7)
Caecal measurements
pH 7.0 (0.03)a 6.6 (0.05)b 6.3 (0.05)c
Tissue weight (g) 0.6 (0.01)a 0.9 (0.02)b 1.1 (0.03)c
Contents weight (g) 1.6 (0.09)a 2.3 (0.11)b 3.8 (0.20)c
Faecal measurements
pH 7.2 (0.04)a 6.9 (0.01)b 6.5 (0.03)c
Faecal output (g/d) 0.6 (0.1)a 1.4 (0.1)b 2.1 (0.2)c
1Mean (SEM), n = 30. See methods for each group’s dietary composition. 2One-way analysis of variance 
with Ryan-Einot-Gabriel-Welsch multiple stepdown post-hoc procedure. Means with a different superscript 
are statistically significantly different at p ≤ 0.05.
Figure 1. Influence of RS on apoptosis in mucosa of distal colon of AOM‑ 
treated rats (n = 15). Values are mean ± SEM. *p < 0.01 compared with 
Control group.
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Effect of the diets on colonic carbohydrate fermentation. Table 4 
summarizes the SCFA concentrations in caecum, proximal and distal 
colonic content and faeces of rats fed the experimental diets.
The SCFA concentrations in the caecum were approximately 
twice those of the faeces. Caecal total SCFA concentration was 
elevated in the HAS groups compared with Control. The analysis 
of the individual SCFA showed that HAS groups had significantly 
higher caecal acetate concentrations compared to Control. Caecal 
propionate concentration was highest in the 10% HAS group 
followed by Control and lowest in the 20% HAS group. Butyrate 
concentration in the caecum was the highest in the 20% HAS group 
with a two-fold elevation compared to the 10% HAS and Control 
groups.
The SCFA concentrations in the proximal colonic content were 
slightly lower than that in the caecum. Proximal total SCFA and 
acetate concentration’s was highest in the 10% HAS compared to 
control and 20% HAS group. Proximal propionate concentration 
was highest in the 10% HAS group followed by the Control and 
then the 20% HAS group. Butyrate concentration in the proximal 
colon was highest in the 20% HAS compared to the Control and 
10% HAS groups.
In the distal colon, total SCFA and acetate concentration were 
elevated in the HAS groups compared with the Control group. Distal 
propionate was elevated in the 10% HAS groups compared with the 
Control and 20% HAS groups. Butyrate concentration in the distal 
colonic content was significantly higher in the 10% HAS and 20% 
HAS groups with a 3-fold and 5-fold increase respectively compared 
with the Control group.
In the faeces, total SCFA, acetate and propionate were all signifi-
cantly elevated in the HAS groups compared with the Control group. 
Butyrate concentration in the faeces was significantly higher in the 
20% HAS group compared to the Control group.
Association of caecal, colonic and faecal parameters with apop-
tosis, cell proliferation and colon cancer incidence. Apoptosis 
in the distal colon was found to be significantly associated with a 
number of parameters in the caecum and faeces after controlling for 
the effect of the different diets (Table 5). Significant relationships 
were seen between caecal pH (p < 0.05) and caecal total SCFA (p < 
0.01), caecal acetate (p < 0.01) and caecal butyrate (p < 0.05) with 
distal apoptosis. Relationships for faecal total SCFA and acetate with 
apoptosis in the distal colon were also observed. A strong relationship 
was seen for caecal pH and cell proliferation (p < 0.01) while a weak 
negative relationship was observed for faecal total SCFA and faecal 
butyrate with cell proliferation (p < 0.05) (Table 5).
For colon cancer incidence there was a significant relationship 
with caecal pH (p < 0.05), while negative relationships were observed 
with total distal SCFA (p < 0.05), distal acetate and distal butyrate 
concentrations (p < 0.05) (Table 5).
dIscussIon
In the present study, we provide clear evidence that consumption 
of a diet rich in RS suppresses AOM-induced colon tumor develop-
ment, as assessed in terms of tumor incidence and multiplicity in 
male Sprague-Dawley rats. This protection was achieved by feeding 
a diet containing 10% or 20% high amylose cornstarch. This might 
have important implications for humans because the proportion of 
starch consumed as RS in the 10% HAS diet is feasible in the context 
of the human diet and not likely to create a serious problem of side 
effects such as flatulence and bloating.11,25
RS in the form of high amylose starch appears to be an excellent 
substrate for the colonic microflora, this was evidenced in the present 
study by promoting fermentation throughout the large bowel. In 
the distal colon, the site where tumors predominate,26 total SCFA 
concentrations including butyrate were markedly increased with HAS 
feeding. Butyrate is considered to be protective against colon cancer.27 
Studies in vivo have indicated that providing the colonic production 
of butyrate through fermentation is active in the distal colon then 
Table 3	 Effect	of	resistant	starch	on	the	proportion		
	 and	number	of	azoxymethane‑induced	colonic		
	 neo	plasms
dietary Group control  10% HAs  20% HAs 
  n = 30 n = 30  n = 30
Proportion of rats developing neoplasia (%)1,3
All Colonic Neoplasms 63 (9) 40 (9) 37 (9)a
 adenomas 10 (5) 13 (8) 13 (8) 
 cancer 57 (11) 27 (10)b 27 (10)b
Number of neoplasms per rat colon2
 all colonic neoplasms 0.73 (0.11) 0.50 (0.12) 0.50 (0.16) 
 adenomas 0.10 (0.06) 0.17 (0.08) 0.20 (0.10) 
 cancer 0.63 (0.11)    0.33 (0.11)a 0.30 (0.10)a
1Proprtion (SE) and using log binomial generalized linear model. 2Mean (SEM) and using Poisson 
regression model. 3Compared to Control: ap ≤ 0.05, bp ≤ 0.01.
Table 4	 Effects	of	resistant	starch	and	indigestible		
	 protein	on	caecal,	proximal	and	distal	colon	and	
	 faecal	SCFA	concentrations	(mmol/g)	in	rats1,2
  treatment Group
 control 10% HAs 20% HAs
Caecal content 
Total SCFA 89.2 (4.6)a 122.2 (6.6)b 127.2 (8.6)b 
Acetate 56.1 (3.2)a 80.6 (5.0)b 84.9 (6.0)b 
Propionate 19.3 (1.0)b 26.9 (1.8)c 10.4 (1.0) a 
Butyrate 8.7 (0.8)a 10.3 (0.7)a 26.3 (2.5) b
Proximal colon 
Total SCFA 63.1 (9.4)a 116.6 (7.0)b 83.3 (4.0)a 
Acetate 40.0 (6.6)a 82.1 (5.5)b 57.9 (3.3)a 
Propionate 13.0 (2.2)b 21.7 (2.3)c 5.8 (1.0)a 
Butyrate 6.1 (0.8)a 9.9 (1.1)a 16.8 (2.3) b
Distal colon
Total SCFA 41.0 (5.4)a 101.1 (12.3)b 89.1 (8.7)b 
Acetate 27.0 (4.1)a 63.0 (8.9)b 58.6 (6.4)b 
Propionate 6.9 (1.1)a 21.6 (2.5)b 7.2 (1.1)a 
Butyrate 3.8 (0.5)a 12.3 (1.8)b 19.5 (3.0)b
Faeces
Total SCFA 35.3 (2.9)a 64.2 (7.4)b 64.6 (6.8)b 
Acetate 22.2 (2.0)a 39.9 (5.6)b 40.4 (5.6)b 
Propionate 6.2 (0.7)a 13.2 (1.4)b 8.6 (1.1)a 
Butyrate 3.9 (0.5)a 6.9 (1.1)ab 10.8 (1.6)b
1Mean (SEM), n = 30. See methods for each group’s dietary composition. 2One-way analysis of variance 
with Ryan-Einot-Gabriel-Welsch multiple stepdown post-hoc procedure. Means with a different superscript 
are statistically significantly different at p ≤ 0.05.
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protection against tumorigenesis is achieved.17 Furthermore, high 
butyrate producing substrates16 and delivery of butyrate directly to 
the distal colonic mucosa28 have been linked to protection against 
the initial stages of colon carcinogenesis. The present study supports 
a role of butyrate in colorectal cancer protection as a significant nega-
tive correlation was observed between butyrate concentration in the 
distal colon and colonic tumor incidence.
In our study apoptosis was significantly increased in the distal 
colon of the HAS groups 25 weeks after the last AOM injection. 
Apoptosis is an important regulatory process in the protection against 
the development of cancer. Apoptosis provides an innate cellular 
defence against oncogenesis by processes that include removal of cells 
with genomic instability that have developed during oncogenesis29 
and by deletion of cells suffering DNA insult from genotoxic agents 
such as carcinogens.30 Analysis of the present data showed that total 
SCFA, acetate and butyrate concentrations in the caecum correlated 
with apoptosis in the distal colon. This is consistent with the in 
vitro data that show apoptosis is induced by SCFA (acetate, propio-
nate and butyrate, with butyrate being the most effective.31 Few in 
vivo studies examining tumorigenesis with intervention by RS or 
other fermentable substrates have investigated the colonic apoptotic 
response at this late time point. Bauer-Marinovic et al.8 however 
did observe a significant increase in apoptosis in rats fed hydrother-
mally treated RS3. In this particular study apoptosis was measured 
in the colon of rats that had received an intensive and prolonged 
carcinogen schedule, namely 20 s.c. injections of DMH where the 
rats were killed one week after the last DMH injection. Previous 
studies from our laboratory have shown that fermentable substrates 
such as HAS or wheat bran can increase the acute apoptotic response 
to a genotoxic carcinogen, whereby apoptosis is measured 6 h after 
carcinogen injection, furthermore this increase correlates with the 
concentration of butyrate.24,32 Increased apoptosis during initiation 
events might enhance the elimination of mutated cells that might 
otherwise progress to malignancy.33 Such an effect is likely to further 
contribute to how RS acts to protect against colorectal tumorigenesis. 
Our results also showed reduced cell proliferation in the distal colon 
of the rats fed the RS containing diets. Increased cell turnover may 
enhance the risk of mutations which can lead to an increased risk of 
developing colorectal cancer.34 Similar reductions in cell proliferation 
were observed in rats fed a RS3
8 or the carbohydrate oligofructose35 
which also demonstrated protection against colorectal tumorigenesis. 
It is likely that the increased SCFA production via fermentation of 
starch in the colon contributes to the homeostatic maintenance of 
the colonic epithelium, this effect is likely to play a role in protection 
against colon tumorigenesis in the present study.
RS may also protect through broader mechanisms associated with 
fermentation. RS has prebiotic properties.36,37 Previous studies in 
rats have shown that as little as 10% HAS in the diet is capable of 
stimulating the production of desirable bacterial species like lactoba-
cilli and bifidobacteria.21 RS in the current study was able to induce 
positive changes in the luminal microenvironment such as acidifica-
tion of digesta and increased faecal bulk both which may contribute 
to enhanced colonic health for the host.11 It has been reported that 
RS is also important in maintaining colonic mucus barrier.38,39 The 
mucus layer covering the colonic mucosa is considered the first line of 
defence against harmful products arising from the luminal content.40 
Breakdown of mucosal barrier integrity is often observed in diseases 
such as inflammatory bowel disease which is a documented risk 
factor for colon cancer.41 RS through enhanced production of SCFA, 
particularly butyrate, may be a means by which the colonic mucus 
barrier is maintained.
In conclusion, the present results show that feeding RS as HAS 
suppresses colorectal cancer induced by AOM exposure in rats. We 
observed increased SCFA production including butyrate from the 
fermentation of the RS, as well as enhanced apoptosis and reduced 
Table 5	 Correlations	between	apoptosis	and	cell		 	
	 proliferation	and	colon	cancer	incidence		 	
	 with	selected	faecal	and	caecal	parameters1
 Apoptosis cell  colon  
  Proliferation cancer (%)
  (r) p‑value (r) p‑value (r) p‑value
Caecum
pH ‑0.34 <0.05 0.59 <0.01 0.24 0.03 
Total SCFA (mmol/g) 0.42 <0.01 ‑0.20 0.34 ‑0.18 0.10 
Acetate 0.42 <0.01 ‑0.21 0.33 ‑0.19 0.09 
Propionate 0.10 0.52 0.10 0.64 ‑0.07 0.56 
Butyrate 0.31 <0.05 ‑0.32 0.13 ‑0.11 0.31
Proximal colon
Total SCFA 0.24 0.31 ‑0.15 0.71 ‑0.27 0.15 
Acetate 0.32 0.19 ‑0.27 0.48 ‑0.25 0.18 
Propionate ‑0.40 0.87 ‑0.03 0.94 ‑0.13 0.51 
Butyrate 0.26 0.29 0.14 0.72 ‑0.26 0.16
Distal colon
Total SCFA 0.33 0.13 ‑0.01 0.97 ‑0.38 0.02 
Acetate 0.31 0.15 ‑0.05 0.88 ‑0.36 0.04 
Propionate 0.18 0.4 ‑0.04 0.92 ‑0.17 0.32 
Butyrate 0.26 0.24 0.21 0.54 ‑0.37 0.03
Faeces
pH ‑0.31 0.07 0.54 <0.05 0.14 0.39 
Total SCFA 0.35 <0.05 ‑0.46 <0.05 ‑0.05 0.79 
Acetate 0.33 <0.05 ‑0.42 0.06 ‑0.02 0.92 
Propionate 0.21 0.21 ‑0.17 0.48 ‑0.08 0.62 
Butyrate 0.25 0.14 ‑0.46 <0.05 ‑0.0.7 0.66
1The relationship between caecal, colonic and faecal variables with apoptosis2 and cell proliferation2 and 
colon tumor incidence3 was done by partial correlation controlling for different diets. 2n = 15; 3n = 30.
Figure 2. Influence of RS on PCNA labelling index in mucosa of distal colon 
of AOM‑treated rats (n = 15). Values are mean ± SEM. *p < 0.01 compared 
with Control group.
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Resistant Starch Protects Against Colorectal Cancer 
cell proliferation in the colonic epithelium. These findings support 
the hypothesis that starch that is resistant to digestion in the small 
intestine can positively influence the colonic luminal environment 
and protect against colorectal cancer.
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